Corpus ID: 54854991

Role of proteasome-ubiquitination degradation pathway in animal cancer - an insight.

@article{Shiwani2014RoleOP,
  title={Role of proteasome-ubiquitination degradation pathway in animal cancer - an insight.},
  author={S. Shiwani and Lee Sung-jin and N. K. Singh},
  journal={Research Opinions in Animal & Veterinary Sciences},
  year={2014},
  volume={4},
  pages={224-232}
}
Most intracellular proteins are degraded by the proteasome, a multicatalytic enzyme complex containing a 20S catalytic core and two 19S regulatory complexes. The proteasome is responsible for the degradation of intracellular proteins that are particularly involved in cell cycle control and the regulation of apoptosis. Preclinical studies have in the past used various forms of proteosome inhibitors such as chemical (Bortezomib), natural resources (marine microbial metabolites, green tea… Expand

Figures and Tables from this paper

References

SHOWING 1-10 OF 52 REFERENCES
Proteasome inhibitors as therapeutic agents: current and future strategies.
  • 52
  • PDF
Development of the proteasome inhibitor PS-341.
  • 348
  • PDF
The proteasome as a target for cancer therapy.
  • 385
  • PDF
The proteasome: structure, function, and role in the cell.
  • J. Adams
  • Biology, Medicine
  • Cancer treatment reviews
  • 2003
  • 495
Inhibition of proteasome deubiquitinating activity as a new cancer therapy
  • 314
  • PDF
The proteasome: a novel target for cancer chemotherapy
  • 470
  • PDF
Proteasomes can degrade a significant proportion of cellular proteins independent of ubiquitination.
  • 156
The proteasome: a macromolecular assembly designed for controlled proteolysis.
  • 118
A mechanism of ubiquitin-independent proteasomal degradation of the tumor suppressors p53 and p73.
  • 322
  • Highly Influential
  • PDF
...
1
2
3
4
5
...